The value of PegFilgastrim for the therapy of acute myeloid leukemia

Acute myeloid leukemia (AML) is a malignant disease resulting from acquired mutations that block the differentiation of primitive hematopoietic cells and thereby cause immature myeloid precursors to accumulate. Patients are often neutropenic as a result of the disease, and intensive chemotherapy will unavoidably exacerbate myelosuppression. However, since the life expectancy is directly correlated to the achievement of complete remission (CR), the goal of induction and consolidation treatment is to induce CR and prevent relapse.